Seres Therapeutics, Inc. — Director's Dealing 2016

Mar 29, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Seres Therapeutics, Inc. (MCRB)
CIK: 0001609809
Period of Report: 2016-03-28

Reporting Person: Aunins John G. (Chief Technology Officer & EVP)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-28	Common Stock	S	9390	$23.89	Disposed	74700	Direct

Footnotes

F1: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $23.77 to $24.78. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.